← Corbus Pharmaceuticals Holdings, Inc. (CRBP) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Pharmaceutical Preparations · market cap $152M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-01 (est.)
Phase 2
Pipeline
6
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Corbus Pharmaceuticals (CRBP) is a clinical-stage pharmaceutical company with 28 employees and a $179M market cap, running a multi-asset pipeline anchored by lenabasum in Phase 3 for dermatomyositis and cystic fibrosis, alongside two Phase 2 oncology antibody programs (CRB-601 and CRB-701). The company carries only $25.7M in cash against a burn rate that implies roughly 3 months of runway, making near-term financing an existential operational concern.
The catalyst path
- 2026-11-01 (est.)Phase 2 · CRB-601 monoclonal antibodyimp 7/10
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-01-16 (est.)Phase 2 · CRB-701imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Lenabasum 5 mg | Phase 3 | Dermatomyositis |
| JBT-101 (lenabasum) | Phase 2 | Cystic Fibrosis |
| CRB-601 monoclonal antibody | Phase 2 | Solid Tumor |
| CRB-701 | Phase 2 | Solid Tumor, Adult |
| Lenabasum 20 mg | Phase 3 | Cystic Fibrosis |
| JBT-101 | Phase 2 | Systemic Lupus Erythematosus |
Price & technical context
3-month
-31.5%
6-month
-36.5%
12-month
-49.9%
52-wk range
$6.34–$19.36
vs 50-day MA
-31.1%
vs 200-day MA
-29.5%
Realized vol
84.6%
Max drawdown
-91.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CRBP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.